about us


Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease. The Company’s proprietary product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, Pulmatrix is pursuing opportunities in major pulmonary diseases through collaboration with partners, including PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease.


Pulmatrix Profile – Health and Science Report


Pulmatrix’s iSPERSE™: An Engineered Solution to Effectively Treat Respiratory Diseases



Recent News
AAA8 – 2018 – Efficacy of PUR1900, An Inhaled Antifungal Therapy, in a Guinea Pig Model of Invasive Pulmonary Aspergillosis / PDF
Mar 14, 2019

Pulmatrix, Inc. (NASDAQ: PULM) announced today that members of its management team will present/participate in investor meetings at the following upcoming conferences: Oppenheimer's 29th Annual...

Mar 12, 2019

Pulmatrix, Inc. (NASDAQ: PULM) announced today that it received a letter from the listing qualifications department staff of The NASDAQ Stock Market LLC, stating that the Company has regained...

Feb 19, 2019

Pulmatrix, Inc. (NASDAQ: PULM) today announces 2018 financial results, reviews the Company's recent progress, and provides an outlook for its pulmonary disease development pipeline. "The funds...

Monday, January 11, 2016
5:30pm - 6:00pm EST
Wednesday, March 9, 2016
11:20am - 11:50am EST

print email
© 2015 Pulmatrix, Inc. All Rights Reservedhome   about pulmatrix   platform   pipeline   investors   careers   contact   site design